Canaccord Genuity Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Model Revisions Ahead of DIFICID Launch
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR), PT $20.
Canaccord analyst says, "Following a recent positive vote ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Following a recent positive vote ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
